EAY191-N4 is a sub-study of the ComboMATCH treatment trial for people that have recurrent or persistent ovarian and endometrial cancers with a RAS pathway mutation. The ComboMATCH registration trial studies show how well treatment that is directed by genetic testing works in treating patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment option that has been shown to prolong overall survival.
EAY191-N4 will test if the drug selumetinib or the combination of selumetinib and the drug olaparib will help improve outcomes for patients whose cancer has RAS pathway genetic changes.
More information about this particular study is located on ClinicalTrials.gov
Are you interested in joining the study? Find a participating location
Below, you can find FAQs about clinical research and this particular clinical trial.
There is currently no agreed upon approach for treating cancers with the genetic changes that you have, RAS pathway mutation. The usual approach for patients who are not in a study is treatment with either surgery, radiation, or with drugs. Sometimes combinations of these treatments are used. Your doctor can explain which treatment may be best for you. These treatments can reduce symptoms and may stop the tumor from growing for several months or more.
The usual approach for patients with recurrent ovarian cancer who are not in a study is treatment with single agent chemotherapy. FDA-approved medicines for recurrent ovarian cancer that is no longer responding to carboplatin include pegylated liposomal doxorubicin, topotecan or weekly paclitaxel. For patients with low grade serous ovarian cancer, hormonal regimens may also be used. None of these medicines have been shown to help patients with recurrent ovarian cancer live longer.
The usual approach for patients with recurrent endometrial cancer is platinum-based chemotherapy or hormonal therapy. In the second line, FDA-approved medicines for recurrent endometrial cancer include pembrolizumab and dostarlimab, which are immune check point inhibitors, for tumors that have a marker called microsatellite instability, or a combination of pembrolizumab and a medicine called lenvatinib for tumors that do not have that marker. These medicines have been shown to help patients with recurrent endometrial cancer live longer and should be considered before participating in this trial. For patients who get the usual approach for this cancer, about 18 out of 100 are free of cancer after 5 years.
Talk to your insurance provider and make sure that you understand what your insurance pays for and what it doesn’t pay for if you take part in this clinical trial. Also, find out if you need approval from your plan before you can take part in the study.
You will not be paid for taking part in this study.
Doctors and researchers conduct a clinical study, also called a “clinical trial,” to find better ways to prevent, diagnose, or treat an illness. NRG Oncology is supported by the National Cancer Institute (NCI) and runs clinical studies specifically for patients with cancer or to prevent cancer. Most clinical studies test something we know against something we don’t know. In all situations, these studies are strictly evaluated before they are allowed to be offered to any patient. The study is designed to answer the question that we do not know the answer to, so that current and future patients may have better treatments or information than what we currently have. There are different types of clinical studies that might be available for patients. For more information see “Types of Clinical Trials” and “Phases of Clinical Trials”.
Patients who volunteer to take part in a clinical study are followed closely by their health care professionals and members of the research team. For more information see “Research Team Members”.
At NRG Oncology, we focus on conducting clinical studies aimed to improve current cancer care practices and the lives of cancer patients. NRG Oncology partners with more than 1,300 member sites world-wide to research ways to improve treatment standards in the cancer community. Our organization is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trial's Network.